Patents by Inventor Jean-Francois Lucien Maisonneuve

Jean-Francois Lucien Maisonneuve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selectively disrupted whole-cell vaccine
    Patent number: 9827299
    Abstract: The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell Streptococcus pneumoniae by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: November 28, 2017
    Assignees: Children's Medical Center Corporation, Path Vaccine Solutions, Fundacao Butantan
    Inventors: Richard Malley, Porter Anderson, Yingjie Lu, George A. Robertson, Mark Alderson, Jean-Francois Lucien Maisonneuve, Andrea Maria Tate, Waldely de Oliveira Dias, Viviane Maimoni Gonçalves
  • EVOKING PROTECTION AGAINST STREPTOTOCCUS PNEUMONIAE INCORPORATING B-CELL AND T-CELL PNEUMOCOCCAL PROTEIN ANTIGENS AND PNEUMOCOCCAL POLYSACCHARIDES DELIVERED CONCOMITANTLY
    Publication number: 20150079132
    Abstract: This disclosure is directed to compositions that combine the polysaccharide-specific antibody protection afforded by the conventional vaccines through carrier effects provided by one or more pneumococcal common T-cell antigen(s) together with Streptococcus pneumoniae-specific Th-17 responses elicited by the pneumococcal carrier common T-cell antigen. The disclosed compositions are useful for pan-serotypic protection against NP carriage, and antibody responses against common pneumococcal virulence factors, potentially useful for pan-serotype protection against Streptococcus pneumoniae invasive diseases.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 19, 2015
    Applicant: PATH
    Inventors: Jean-Francois Lucien Maisonneuve, Mark Raymond Alderson
  • SELECTIVELY DISRUPTED WHOLE-CELL VACCINE
    Publication number: 20120251577
    Abstract: The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell Streptococcus pneumoniae by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.
    Type: Application
    Filed: October 12, 2010
    Publication date: October 4, 2012
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, FUNDACAO BUTANTAN, PATH VACCINE SOLUTIONS
    Inventors: Richard Malley, Porter Anderson, Yingjie Lu, George A. Robertson, Mark Alderson, Jean-Francois Lucien Maisonneuve, Andrea Maria Tate, Waldely de Oliveira Dias, Viviane Maimoni Gonçalves
  • Vaccines
    Publication number: 20030219453
    Abstract: Vaccine preparations are provided for the prevention of Chylamydia infections comprising a major outer membrane protein from chlamydia and a mucosal adjuvant such as a combination of QS21 and 3D-MPL, or chlorea Toxin or Heat labile enterotoxin. Such preparations provide protection from Chlamydia induced fertility.
    Type: Application
    Filed: November 6, 2002
    Publication date: November 27, 2003
    Applicant: SmithKline Beecham Biologicals, sa
    Inventors: Jean-Francois Lucien Maisonneuve, Jean-Paul Prieels, Moncef-Mohamed Slaoui, Vincent Georges Christian Louis Verlant